Metastatic Prostate Cancer

This course gives clinicians a complete view on clinical aspects, diagnosis and treatments of castrate-sensitive and castrate-resistant metastatic prostate cancer (mPCa). This e-learning course offers an overview on the state-of-the-art of the clinical diagnosis and treatment of mPCa. This course is divided in 2 modules that show an in-depth approach to both cases castrate-sensitive and castrate-resistant prostate cancer and their treatments.

The development of this course has been supported by Jansen and Ipsen with a concession of an unrestricted educational grant.

Learning Objectives

Users of this training are expected to progress their knowledge in the clinical aspects and management of metastatic prostate cancer.

Specific learning objectives are as follows:

– Definition of castrate-sensitive and castrate-resistant metastatic prostate cancer
– How to detect suspicious symptoms in a case of known or unknown prostate cancer.
– Which imaging technology to apply in a certain situation.
– Study of the molecular mechanisms of various treatments.
– The correct treatment: practical aspects, correct timing to start, relationship with disease pathology, etc.
– Clinical and biological follow-up and monitoring of mPCa patients.
– How to use nomograms to determine the prognosis of the patient.

Learning Modules

Learning Module A: Metastatic PCa
1. Definition and classification
2. Clinical evaluation
3. Treatment
4. Follow-up and surveillance

Learning Module B: Castrate Resistant PCa
1. Definition
2. Clinical evaluation

At a glance

• Publication date: November 2016
• Available languages: English
• Topic: castrate-sensitive and castrate-resistant metastatic prostate cancer (MPCa)
• Duration: 90 minutes per module approximately
• CME: An application has been made to the EACCME® for CME accreditation of this course

Contributing Authors

Main author:
Prof. Dr. N. Mottet (Chair of the EAU PCa Guidelines Panel)

Prof. Dr. A.S. Merseburger (RCC Guidelines Panel member)